Viveve Medical Inc (VIVE) Expected to Post Earnings of -$0.46 Per Share

Equities analysts expect Viveve Medical Inc (NASDAQ:VIVE) to announce ($0.46) earnings per share for the current quarter, according to Zacks. Three analysts have made estimates for Viveve Medical’s earnings, with the highest EPS estimate coming in at ($0.42) and the lowest estimate coming in at ($0.48). Viveve Medical reported earnings per share of ($0.55) in the same quarter last year, which indicates a positive year over year growth rate of 16.4%. The business is scheduled to announce its next quarterly earnings results on Thursday, February 15th.

According to Zacks, analysts expect that Viveve Medical will report full-year earnings of ($2.04) per share for the current financial year, with EPS estimates ranging from ($2.08) to ($1.97). For the next fiscal year, analysts expect that the company will report earnings of ($1.59) per share, with EPS estimates ranging from ($1.75) to ($1.47). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Viveve Medical.

Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.08). The firm had revenue of $4.07 million during the quarter, compared to analyst estimates of $4.10 million. Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. Viveve Medical’s quarterly revenue was up 120.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.46) earnings per share.

A number of equities analysts have weighed in on the stock. Cowen set a $11.00 target price on shares of Viveve Medical and gave the stock a “buy” rating in a research note on Monday, October 23rd. ValuEngine raised shares of Viveve Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Mizuho assumed coverage on shares of Viveve Medical in a research note on Thursday, November 16th. They issued a “buy” rating and a $10.00 target price for the company. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Viveve Medical presently has a consensus rating of “Buy” and a consensus price target of $10.40.

Viveve Medical (VIVE) traded up $0.10 during trading hours on Wednesday, reaching $5.00. 70,500 shares of the company’s stock were exchanged, compared to its average volume of 178,027. The firm has a market capitalization of $95.19, a price-to-earnings ratio of -2.31 and a beta of -0.65. Viveve Medical has a 52-week low of $3.75 and a 52-week high of $11.16. The company has a debt-to-equity ratio of 2.72, a quick ratio of 3.63 and a current ratio of 3.89.

Hedge funds and other institutional investors have recently made changes to their positions in the business. TIAA CREF Investment Management LLC bought a new position in shares of Viveve Medical in the second quarter worth about $296,000. ING Groep NV raised its stake in shares of Viveve Medical by 93.7% during the third quarter. ING Groep NV now owns 325,000 shares of the company’s stock worth $1,703,000 after buying an additional 157,200 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Viveve Medical by 135.4% during the second quarter. Vanguard Group Inc. now owns 450,142 shares of the company’s stock worth $3,232,000 after buying an additional 258,912 shares during the last quarter. Numeric Investors LLC bought a new stake in shares of Viveve Medical during the second quarter worth approximately $330,000. Finally, RTW Investments LP raised its stake in shares of Viveve Medical by 18.8% during the third quarter. RTW Investments LP now owns 1,473,028 shares of the company’s stock worth $7,719,000 after buying an additional 233,585 shares during the last quarter. 66.90% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/12/27/viveve-medical-inc-vive-expected-to-post-earnings-of-0-46-per-share.html.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Get a free copy of the Zacks research report on Viveve Medical (VIVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viveve Medical (NASDAQ:VIVE)

What are top analysts saying about Viveve Medical? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Viveve Medical and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit